D. Boral Capital Reiterates Buy Rating for Anavex Life Sciences (NASDAQ:AVXL)

D. Boral Capital restated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL – Free Report) in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a $46.00 price objective on the biotechnology company’s stock. Separately, HC Wainwright restated a “buy” rating and issued a $40.00 target price on […]

Leave a Reply

Your email address will not be published.

Previous post MGP Ingredients (NASDAQ:MGPI) Sets New 12-Month Low Following Analyst Downgrade
Next post Comparing SK Growth Opportunities (SKGR) & The Competition